Ginsenoside-Rd improves outcome of acute ischaemic stroke-a randomized, double-blind, placebo-controlled, multicenter trial

European Journal of Neurology, 03/09/2012

Ginsenoside–Rd improved the primary outcome of acute ischaemic stroke and had an acceptable adverse–event profile.


  • The authors conducted a randomized, double–blind, placebo–controlled trial involving 390 patients with acute ischaemic stroke in a 3:1 ratio to receive a 14–day intravenous infusion of Ginsenoside–Rd or placebo within 72 h after the onset of stroke.
  • The primary end–point was the distribution of disability scores on the modified Rankin scale (mRs) at 90 days.


  • The efficacy analysis was based on 386 patients (Ginsenoside–Rd group: 290; placebo group: 96).
  • Ginsenoside–Rd significantly improved the overall distribution of scores on the mRs, as compared with the placebo (P = 0.02; odds ratios [OR], 1.74; 95% confidence interval [CI], 1.08–2.78).
  • There were significant differences between the two groups when they categorized the scores into 0–1 vs. 2–5 (P = 0.01; OR, 2.32; 95% CI, 1.23–4.38; 66.8% vs. 53.1%).
  • It also improved the National Institutes of Health Stroke Scale (NIHSS) at 15 days [P < 0.01; least squares mean (LSM), –0.77; 95% CI, –1.31 to –0.24]. Mortality and rates of adverse events were similar in the two groups.

Print Article Summary Cat 2 CME Report